Tenofovir Disoproxil Fumarate Market - Forecast(2023 - 2028)

Tenofovir Disoproxil Fumarate Market Overview

The Tenofovir Disoproxil Fumarate Market size is estimated to grow at a CAGR of around 4.5% from 2022 to 2027. Tenofovir disoproxil fumarate also called viread, is a medication which is used to treat chronic hepatitis B and in prevention of HIV/AIDS. Tenofovir is a derivative of adenine and has phosphonate residue as active ingredient. The drug as nucleotide reverse transcriptase inhibitor prevents the HIV and hepatitis B virus from multiplying in human body and is available as generic medication also. Factors like growing cases of hepatitis B, increase in female HIV patients and growing efforts by countries to achieve viral suppression against HIV are driving the growth of Tenofovir Disoproxil Fumarate Market. However, the side effects of the drug such as nausea, rash, diarrhea, headache, pain, depression can restrict its usage in medical sector for HIV & hepatitis B treatment. This can hamper the growth of global tenofovir disoproxil fumarate industry.

COVID-19 Impact

The lockdown implemented by countries across the world in order to curb the effect of COVID-19 virus, had a negative impact on production and supply of certain medicines on account of a lack of raw materials and workforce availability. For instance, according to quarterly statement of Gilead Sciences Inc. in Q4 of 2020, HIV product sales decreased 7% to US$4.3 billion as compared to US$4.6 billion made in Q4 of 2019. Further, as per another report by Gilead, in Q2 of 2020, company’s hepatitis sales decreased by 47% to US$448 million compared to US$842 million worth of sales made in Q2 of 2019. Tenofovir disoproxil fumarate as nucleotide reverse transcriptase inhibitor is majorly used in treatment of hepatitis B and prevent spreading of HIV virus in humans. Hence, the decrease in the sales volume of HIV and hepatitis product on account of COVID negatively impacted the usage of tenofovir disoproxil fumarate for HIV and hepatitis B treatment. This decreased the growth of global tenofovir disoproxil fumarate industry.

Report Coverage

The “Tenofovir Disoproxil Fumarate Market Report – Forecast (2022 – 2027)”, by IndustryARC, covers an in-depth analysis of the following segments of the Tenofovir Disoproxil Fumarate industry.

By Form – Tablets and Powder
By Packaging– Box and Bottles
By Application – HIV Treatment and Chronic Hepatitis B Treatment
By End User – Pregnant Women, Nursing Mothers, Pediatric Patients, Geriatric Patients, Impaired Renal Function Patients, and Others 
By Geography - North America (USA, Canada, Mexico), Europe (UK, Germany, France, Italy, Netherland, Spain, Russia, Belgium, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and New Zealand, Indonesia, Taiwan, Malaysia, Rest of APAC), South America (Brazil, Argentina, Colombia, Chile, Rest of South America), Rest of the World (Middle East, Africa)

Key Takeaways

• North America dominates the tenofovir disoproxil fumarate industry as the region consist of leading producers of tenofovir disoproxil fumarate in major economy like US.
• The growing number of hepatitis B and HIV/AIDS related cases globally has led to increase in usage of antiretroviral drugs which has provided growth opportunities for global tenofovir disoproxil fumarate industry.
• Various initiatives taken by government organization such as Ending the HIV Pandemic in US, will lead to more usage of tenofovir disoproxil fumarate in HIV treatment which will expand global tenofovir disoproxil fumarate industry.

Figure: North America Tenofovir Disoproxil Fumarate Market Revenue, 2021-2027 (US$ Million)

Tenofovir Disoproxil Fumarate Market Segment Analysis – By Form

Tablets segment held a significant share in Tenofovir Disoproxil Fumarate Market in 2021 and it is projected to grow with a CAGR of 4.7% during the forecast period. Tenofovir disoproxil fumarate tablets combine a number of antiviral drugs in a single dose and can be available in different dosages like 150gm, 200gm, 250gm and 300gm. Hence, different dosage of tenofovir disoproxil fumarate tablets depends upon the age factor of patients having HIV or hepatitis. The growing number of HIV or hepatitis related cases has positively impacted the usage of tenofovir disoproxil fumarate tablets. For instance, according to World Health Organization, in 2020, 680 000 people died from HIV-related causes and 1.5 million people acquired HIV. Such high number of HIV related deaths and cases will increase the usage of tenofovir disoproxil fumarate tablets which act as nucleotide reverse transcriptase inhibitor and prevent HIV virus from multiplying in body. This will positively impact the growth of global tenofovir disoproxil fumarate industry.

Tenofovir Disoproxil Fumarate Market Segment Analysis – By End User

Pregnant women segment held a significant share in Tenofovir Disoproxil Fumarate Market in 2021 and it is estimated to grow with a CAGR of 3.9% during the forecast period. Tenofovir Disoproxil Fumarate is recommended to women in order to prevent transmitting of HIV to their babies during pregnancy, childbirth and also to protect their own health. The growing awareness regarding HIV among females has positively impacted the usage of tenofovir disoproxil fumarate. For instance, according to data given by Joint United Nations Programme on HIV/AIDS, in 2020, 85% of pregnant women with HIV received antiretroviral therapy to prevent transmitting HIV to their babies during pregnancy and childbirth. Tenofovir disoproxil fumarate having active phosphonate ingredient, is used with antiretroviral to prevent further exposure of HIV/AIDS among pregnant women. Growing number of antiretroviral thereby will increase the usage of antiretroviral among pregnant women resulting in more usage of tenofovir disoproxil fumarate drugs with them. This will boost global tenofovir disoproxil fumarate industry growth.

Tenofovir Disoproxil Fumarate Market Segment Analysis – By Geography

North America is the fastest growing region in Tenofovir Disoproxil Fumarate Market and it is projected to grow with a CAGR of 5.2% during the forecast period. The region consists of major country like US which is hub of companies like Gilead Sciences Inc. which is the leading producers of tenofovir disoproxil fumarate. The increase in number of HIV and hepatitis B patients has increased the sales of Gelatin Sciences Inc. in US. For instance, according to quarterly statement of Gilead, in Q4 of 2021, HIV product sales in US increased 7% to US$4.5 billion compared to 2020 same period. Moreover, hepatitis B virus (“HBV”) product sales increased 9% to US$265 million for Q4 2021 compared to the same period in 2020. Tenofovir disoproxil fumarate available in US as generic medication is used to treat hepatitis B and to prevent HIV exposure. Increase in sales of HIV and hepatitis B drugs will lead to more usage of tenofovir disoproxil fumarate for their treatment, which will boost the growth of global tenofovir disoproxil fumarate industry.

Tenofovir Disoproxil Fumarate Market Drivers

Growing Number of Hepatitis B Patients

Hepatitis B is a serious liver infection which is caused by hepatitis b virus (HBV) and is passed from person to person through blood, semen or other body fluids. Tenofovir disoproxil fumarate as nucleotide reverse transcriptase inhibitor prevent spreading of hepatitis b in body and protect liver from further infection. The growing cases of hepatitis B globally, has positively impacted the demand for tenofovir disoproxil fumarate. For instance, according to World Health Organization, in 2019, 296 million people were living with chronic hepatitis B infection and the virus resulted in an estimated death of 8,20,000 people. Such high number of active cases and death caused by hepatitis B will lead to more usage of tenofovir disoproxil fumarate for its treatment, which will boost the growth of global tenofovir disoproxil fumarate industry.

Increase in Number of Female HIV Patients

Women are more vulnerable to HIV infection than men and the major cause of catching infection is through physical contact. The growing number of female HIV patients globally has led to increase in demand for HIV drugs like tenofovir disoproxil fumarate. For instance, according to data given by Joint United Nations Programme on HIV/AIDS, in 2020, total number of HIV infected people was 37.7 million and women with total number of 19.3 million, accounted 51% share of the total global HIV population. Moreover, in 2020, women and girls in sub-Saharan Africa accounted for 63% of all new HIV infections. Tenofovir disoproxil fumarate having phosphonate active ingredient in it, act as nucleotide reverse transcriptase inhibitor which prevent further growth of HIV virus inside body. The growing number of female HIV patients will lead to more usage of tenofovir disoproxil fumarate for HIV treatment, which will positively impact global tenofovir disoproxil fumarate industry growth.

Tenofovir Disoproxil Fumarate Market Challenges

Side Effects on Health

Common side effects of tenofovir disoproxil fumarate are weakness, depression, headache, diarrhea and pain, while severe side effects consists of high blood lactate and enlarge liver. Hence, such side effects will lead to less usage of tenofovir disoproxil fumarate for certain end users especially geriatric patients. This can hamper the growth of global tenofovir disoproxil fumarate industry.

Tenofovir Disoproxil Fumarate Industry Outlook

The companies to develop a strong regional presence and strengthen their market position, continuously engage in mergers and acquisitions. In tenofovir disoproxil fumarate market report, the tenofovir disoproxil fumarate top 10 companies are:

1. Gilead Sciences Inc.
2. Glaxo Smithkline
3. Zydus Cadila
4. Mylan Pharmaceutical
5. Emcure Pharmaceutical
6. Hetero Drugs
7. Anhui Biochem Pharmaceutical
8. Cipla
9. Qilu Pharmaceutical
10. Dr. Reddy’s Laboratories

Recent Developments

• In 2022, ViiV Healthcare, the global specialist HIV company announced that Food and Drug Administration has approved company’s new drug application for dispersible tablet formulation of fixed dose combination of abacavir, dolutegravir and lamivudine for treatment of pediatric patients having HIV-1.
• In 2021, Gilead and Merck announced agreement to jointly develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV.
• In 2021, Hepatitis B Foundation and Rx Outreach announced a new venture to provide generic Viread® and generic Baraclude® two of the most commonly prescribed medications for chronic hepatitis B at low cost to people across US.

Relevant Reports

Fine Chemicals Market – Forecast (2022 - 2027)

Report Code – CMR 0411

Pharmaceutical Excipients Market – Forecast (2022 - 2027)

Report Code – CMR 0597

Cytokinins Market – Forecast (2022 - 2027)

Report Code – CMR 0426

 For more Chemicals and Materials Market reports, please click here